礼来制药恩格列净成人慢性肾病适应症在中国获批
liuyp1
发表于 2023-11-24 18:17:44
1275
0
0
这是继成人2型糖尿病、射血分数降低的成人心力衰竭和射血分数保留的成人心力衰竭、联合胰岛素治疗2型糖尿病之后,欧唐静®在中国获批的又一个新适应症。加上现有的2型糖尿病和心力衰竭适应症,欧唐静®有助于管理因心-肾-代谢疾病导致的风险。自上市以来,在全球范围内已经累计惠及患者超过10亿人。
中国工程院院士、国家肾脏疾病临床医学研究中心主任刘志红表示,慢性肾病是威胁全世界公共健康的主要疾病,在我国,因为过去十年公众教育、医疗服务和环境保护的改善,18岁以上成年人CKD患病率已由原先的10.8%降至8.2%。但是由于CKD发病率高、合并心血管疾病率高、致死致残率高;知晓率低、就诊率低、控制率低的“三高三低”特征,患者及其家庭乃至社会仍然面临着相当沉重的负担。此次获批使得欧唐静®为中国患者带来安全有效的治疗新选择,有望改善更多CKD患者的治疗前景。
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.